IFN-λ4 is associated with increased risk and earlier occurrence of several common infections in African children.
Journal
Genes and immunity
ISSN: 1476-5470
Titre abrégé: Genes Immun
Pays: England
ID NLM: 100953417
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
03
01
2021
accepted:
29
03
2021
revised:
23
03
2021
pubmed:
15
4
2021
medline:
14
1
2022
entrez:
14
4
2021
Statut:
ppublish
Résumé
Genetic polymorphisms within the IFNL3/IFNL4 genomic region, which encodes type III interferons, have been strongly associated with clearance of hepatitis C virus. We hypothesized that type III interferons might be important for the immune response to other pathogens as well. In a cohort of 914 Malian children, we genotyped functional variants IFNL4-rs368234815, IFNL4-rs117648444, and IFNL3-rs4803217 and analyzed episodes of malaria, gastrointestinal, and respiratory infections recorded at 30,626 clinic visits from birth up to 5 years of age. Compared to children with the rs368234815-TT/TT genotype (IFN-λ4-Null), rs368234815-dG allele was most strongly associated with an earlier time-to-first episode of gastrointestinal infections (p = 0.003). The risk of experiencing an infection episode during the follow-up was also significantly increased with rs368234815-dG allele, with OR = 1.53, 95%CI (1.13-2.07), p = 0.005 for gastrointestinal infections and OR = 1.30, 95%CI (1.02-1.65), p = 0.033 for malaria. All the associations for the moderately linked rs4803217 (r
Identifiants
pubmed: 33850301
doi: 10.1038/s41435-021-00127-7
pii: 10.1038/s41435-021-00127-7
pmc: PMC8042471
doi:
Substances chimiques
IFNL4 protein, human
0
Interleukins
0
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-55Références
Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388:3027–35.
pubmed: 27839855
pmcid: 5161777
doi: 10.1016/S0140-6736(16)31593-8
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
pubmed: 19684573
doi: 10.1038/nature08309
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
pubmed: 19759533
pmcid: 3172006
doi: 10.1038/nature08463
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.
pubmed: 19749758
doi: 10.1038/ng.447
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
pubmed: 19749757
doi: 10.1038/ng.449
Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71.
pubmed: 23291588
pmcid: 3793390
doi: 10.1038/ng.2521
Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16:802–9.
pubmed: 26194286
pmcid: 7096991
doi: 10.1038/ni.3212
Lazear HM, Nice TJ, Diamond MS. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity. 2015;43:15–28.
pubmed: 26200010
pmcid: 4527169
doi: 10.1016/j.immuni.2015.07.001
Prokunina-Olsson L. Genetics of the human interferon lambda region. J Interferon Cytokine Res. 2019;39:599–608.
pubmed: 31070498
pmcid: 6767866
doi: 10.1089/jir.2019.0043
Key FM, Peter B, Dennis MY, Huerta-Sanchez E, Tang W, Prokunina-Olsson L, et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet. 2014;10:e1004681.
pubmed: 25329461
pmcid: 4199494
doi: 10.1371/journal.pgen.1004681
Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, et al. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 2014;5:5699.
pubmed: 25534433
doi: 10.1038/ncomms6699
Gadalla SM, Wang Y, Wang T, Onabajo OO, Banday AR, Obajemu A, et al. Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematol. 2020;7:e715–23.
pubmed: 32976751
doi: 10.1016/S2352-3026(20)30294-5
pmcid: 7735535
McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15:72–9.
pubmed: 24241692
doi: 10.1038/ni.2758
Rugwizangoga B, Andersson ME, Kabayiza JC, Nilsson MS, Armannsdottir B, Aurelius J, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.
pubmed: 31637221
pmcid: 6787560
doi: 10.3389/fcimb.2019.00340
O’Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015;63:1103–10.
pubmed: 26186989
pmcid: 4615534
doi: 10.1016/j.jhep.2015.06.035
Legason ID, Pfeiffer RM, Udquim KI, Bergen AW, Gouveia MH, Kirimunda S, et al. Evaluating the causal link between malaria infection and endemic Burkitt lymphoma in Northern Uganda: a Mendelian randomization study. EBio Med. 2017;25:58–65.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.
pubmed: 15297300
doi: 10.1093/bioinformatics/bth457
Oude Munnink BB, van der Hoek L. Viruses causing gastroenteritis: the known, the new and those beyond. Viruses. 2016;8.42.
Wilhelmi I, Roman E, Sanchez-Fauquier A. Viruses causing gastroenteritis. Clin Microbiol Infect. 2003;9:247–62.
pubmed: 12667234
pmcid: 7129320
doi: 10.1046/j.1469-0691.2003.00560.x
De Grazia S, Bonura F, Bonura C, Mangiaracina L, Filizzolo C, Martella V, et al. Assessing the burden of viral co-infections in acute gastroenteritis in children: an eleven-year-long investigation. J Clin Virol. 2020;129:104513.
pubmed: 32575023
doi: 10.1016/j.jcv.2020.104513
Kabayiza JC, Andersson ME, Nilsson S, Baribwira C, Muhirwa G, Bergstrom T, et al. Diarrhoeagenic microbes by real-time PCR in Rwandan children under 5 years of age with acute gastroenteritis. Clin Microbiol Infect. 2014;20:O1128–35.
pubmed: 24890572
doi: 10.1111/1469-0691.12698
Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172:958–65.
pubmed: 30105384
pmcid: 6233802
doi: 10.1001/jamapediatrics.2018.1960
Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:725–30.
pubmed: 24981041
pmcid: 8006533
doi: 10.1016/S1473-3099(14)70767-4
Saxena K, Simon LM, Zeng XL, Blutt SE, Crawford SE, Sastri NP, et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc Natl Acad Sci USA. 2017;114:E570–9.
pubmed: 28069942
doi: 10.1073/pnas.1615422114
pmcid: 5278484
Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016;353:1387–93.
pubmed: 27562956
pmcid: 5305121
doi: 10.1126/science.aaf5211
Lin JD, Feng N, Sen A, Balan M, Tseng HC, McElrath C, et al. Distinct roles of Type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLoS Pathog. 2016;12:e1005600.
pubmed: 27128797
pmcid: 4851417
doi: 10.1371/journal.ppat.1005600
Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347:269–73.
pubmed: 25431489
doi: 10.1126/science.1258100
Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol. 2015;16:698–707.
pubmed: 26006013
pmcid: 4589158
doi: 10.1038/ni.3180
Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA. 2011;108:7944–9.
pubmed: 21518880
doi: 10.1073/pnas.1100552108
pmcid: 3093475
Baldridge MT, Lee S, Brown JJ, McAllister N, Urbanek K, Dermody TS, et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus. J Virol. 2017;91:7.
doi: 10.1128/JVI.02079-16
Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection. Science. 2015;347:266–9.
pubmed: 25431490
doi: 10.1126/science.1258025
Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25–32.
pubmed: 11892493
doi: 10.1016/S1473-3099(01)00170-0
Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 2011;160:360–6.
pubmed: 21816185
doi: 10.1016/j.virusres.2011.07.011
Klinkhammer J, Schnepf D, Ye L, Schwaderlapp M, Gad HH, Hartmann R et al. IFN-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. 2018;7.
Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol Med. 2016;8:1099–112.
pubmed: 27520969
pmcid: 5009813
doi: 10.15252/emmm.201606413
Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M. et al. Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity. 2017;46:875–90.e6.
pubmed: 28514692
doi: 10.1016/j.immuni.2017.04.025
Kotenko SV, Rivera A, Parker D, Durbin JE. Type III IFNs: beyond antiviral protection. Semin Immunol. 2019;43:101303.
pubmed: 31771761
pmcid: 7141597
doi: 10.1016/j.smim.2019.101303
Samayoa Reyes G, Jackson C, Ogolla S, Obajemu A, Dent AE, Prokunina-Olsson L, et al. IFN-λ4 genetic variants influence clinical malaria episodes in a cohort of Kenyan children. Res Square preprint.
Reisinger EC, Fritzsche C, Krause R, Krejs GJ. Diarrhea caused by primarily non-gastrointestinal infections. Nat Clin Pract Gastroenterol Hepatol. 2005;2:216–22.
pubmed: 16265204
pmcid: 7097032
doi: 10.1038/ncpgasthep0167
Amodio E, Pipitone RM, Grimaudo S, Immordino P, Maida CM, Prestileo T, et al. SARS-CoV-2 viral load, ifnlambda polymorphisms and the course of COVID-19: an observational study. J Clin Med. 2020;9.
Onabajo OO, Muchmore B, Prokunina-Olsson L. The IFN-lambda4 conundrum: when a good interferon goes bad. J Interferon Cytokine Res. 2019;39:636–41.
pubmed: 31241411
pmcid: 6767864
doi: 10.1089/jir.2019.0044